A new generation of treatments for itch

Emilie Fowler, Gil Yosipovitch

Research output: Contribution to journalReview article

Abstract

For decades, antihistamines have been the mainstay of treatment for chronic pruritus, yet they often only work by making patients drowsy and forgetful of their itch. A new era of antipruritic drugs is quickly approaching, presenting more effective treatments for patients suffering from chronic itch. Several treatments have been developed targeting specific receptors in the nervous system, such as the transient receptor potential channels, sodium channels, neurokinin-1 receptors, opioid receptors, and many more. Additionally, antipruritic therapies developed to work on the immune system have become more targeted, leading to greater safety and efficacy measures. These include crisaborole, several interleukin antagonists, and janus kinase inhibitors. The promising results presented with these new antipruritic therapies allow physicians to be better equipped to treat their itchy patients.

Original languageEnglish (US)
Article numberadv00027
Pages (from-to)37-45
Number of pages9
JournalActa dermato-venereologica
Volume100
Issue number1
DOIs
StatePublished - Jan 2020

Fingerprint

Antipruritics
Transient Receptor Potential Channels
Janus Kinases
Therapeutics
Neurokinin-1 Receptors
Sodium Channels
Interleukins
Histamine Antagonists
Opioid Receptors
Pruritus
Nervous System
Immune System
Physicians
Safety

Keywords

  • Antipruritics
  • Cytokines
  • Pruritus
  • Unmyelinated nerve fibers

ASJC Scopus subject areas

  • Dermatology

Cite this

A new generation of treatments for itch. / Fowler, Emilie; Yosipovitch, Gil.

In: Acta dermato-venereologica, Vol. 100, No. 1, adv00027, 01.2020, p. 37-45.

Research output: Contribution to journalReview article

Fowler, Emilie ; Yosipovitch, Gil. / A new generation of treatments for itch. In: Acta dermato-venereologica. 2020 ; Vol. 100, No. 1. pp. 37-45.
@article{c56d02ea936d48c98c79f97e0077309a,
title = "A new generation of treatments for itch",
abstract = "For decades, antihistamines have been the mainstay of treatment for chronic pruritus, yet they often only work by making patients drowsy and forgetful of their itch. A new era of antipruritic drugs is quickly approaching, presenting more effective treatments for patients suffering from chronic itch. Several treatments have been developed targeting specific receptors in the nervous system, such as the transient receptor potential channels, sodium channels, neurokinin-1 receptors, opioid receptors, and many more. Additionally, antipruritic therapies developed to work on the immune system have become more targeted, leading to greater safety and efficacy measures. These include crisaborole, several interleukin antagonists, and janus kinase inhibitors. The promising results presented with these new antipruritic therapies allow physicians to be better equipped to treat their itchy patients.",
keywords = "Antipruritics, Cytokines, Pruritus, Unmyelinated nerve fibers",
author = "Emilie Fowler and Gil Yosipovitch",
year = "2020",
month = "1",
doi = "10.2340/00015555-3347",
language = "English (US)",
volume = "100",
pages = "37--45",
journal = "Acta Dermato-Venereologica",
issn = "0001-5555",
publisher = "Society for the Publication of Acta Dermato-Venereologica",
number = "1",

}

TY - JOUR

T1 - A new generation of treatments for itch

AU - Fowler, Emilie

AU - Yosipovitch, Gil

PY - 2020/1

Y1 - 2020/1

N2 - For decades, antihistamines have been the mainstay of treatment for chronic pruritus, yet they often only work by making patients drowsy and forgetful of their itch. A new era of antipruritic drugs is quickly approaching, presenting more effective treatments for patients suffering from chronic itch. Several treatments have been developed targeting specific receptors in the nervous system, such as the transient receptor potential channels, sodium channels, neurokinin-1 receptors, opioid receptors, and many more. Additionally, antipruritic therapies developed to work on the immune system have become more targeted, leading to greater safety and efficacy measures. These include crisaborole, several interleukin antagonists, and janus kinase inhibitors. The promising results presented with these new antipruritic therapies allow physicians to be better equipped to treat their itchy patients.

AB - For decades, antihistamines have been the mainstay of treatment for chronic pruritus, yet they often only work by making patients drowsy and forgetful of their itch. A new era of antipruritic drugs is quickly approaching, presenting more effective treatments for patients suffering from chronic itch. Several treatments have been developed targeting specific receptors in the nervous system, such as the transient receptor potential channels, sodium channels, neurokinin-1 receptors, opioid receptors, and many more. Additionally, antipruritic therapies developed to work on the immune system have become more targeted, leading to greater safety and efficacy measures. These include crisaborole, several interleukin antagonists, and janus kinase inhibitors. The promising results presented with these new antipruritic therapies allow physicians to be better equipped to treat their itchy patients.

KW - Antipruritics

KW - Cytokines

KW - Pruritus

KW - Unmyelinated nerve fibers

UR - http://www.scopus.com/inward/record.url?scp=85077892894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85077892894&partnerID=8YFLogxK

U2 - 10.2340/00015555-3347

DO - 10.2340/00015555-3347

M3 - Review article

C2 - 31939609

AN - SCOPUS:85077892894

VL - 100

SP - 37

EP - 45

JO - Acta Dermato-Venereologica

JF - Acta Dermato-Venereologica

SN - 0001-5555

IS - 1

M1 - adv00027

ER -